Open Access Full Text Article

LncRNA RNF144A-AS1 Promotes Bladder Cancer Progression via RNF144A-AS1/miR-455-5p/SOX11 Axis [Retraction]

Bi H, Shang Z, Jia C, et al. Onco Targets Ther. 2020;13:11277-11288.

The Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. Concerns were raised following the authors request to replace duplicated images in Figure 2E and 2F and Figure 5F and 5G. Specifically,

- Figure 2E, J82 si-NC appears to have been duplicated with Figure 2E, 5637 si-NC and Figure 2F, J82 si-NC.
- Figure 2E, J82 si-RNF144A-AS1 appears to have been duplicated with Figure 2E, 5637 si-RNF144A-AS1 and Figure 2F, J82 si-RNF144A-AS1.
- Figure 5F, J82 si-NC appears to have been duplicated with Figure 5F, 5637 si-RNF144A-AS1+OE SOX11.
- Figure 5F, J82 si-RNF144A-AS1 appears to have been duplicated Figure 5F, 5637 si-RNF144A-AS1.
- Figure 5G, J82 si-NC appears to have been duplicated with Figure 5G, J82 si-RNF144A-AS1+OE SOX11 and Figure 5G, 5637 si-NC.
- Figure 5G, J82 si-RNF144A-AS1 appears to have been duplicated with Figure 5G, 5637 si-RNF144A-AS1.

The authors responded to our queries but could not provide a satisfactory explanation for the number of duplicated images that occurred. The authors also provided some original data, but this was not satisfactory and was unable to verify the reported findings. The decision was made to retract the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

OncoTargets and Therapy

Dovepress

68 I

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S378352

OncoTargets and Therapy 2022:15 681

© 2022 Dove Medical Press. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraph 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).